BACKGROUND: Health care utilization in older adults (age ≥60 years) with acute myeloid leukemia (AML) has not been well studied. METHODS: We conducted a retrospective analysis of 330 consecutive older patients who were diagnosed with AML between May 1, 2005 and December 23, 2011, at 2 hospitals in Boston to examine their health care utilization and end-of-life care. Using multivariable logistic and linear regression models adjusting for covariates, we also compared health care utilization between patients who received intensive induction chemotherapy (n = 197; cytarabine/ anthracycline combination) versus nonintensive chemotherapy (n = 133; single-agent therapy). RESULTS: The median number of hospitalizations for the entire cohort was 4.2 (range, 1-18 hospitalizations). Patients who died spent a mean of 28.3% of their life after diagnosis in the hospital and 13.8% of their life attending outpatient clinic appointments. Although the majority of patients (87.9%) died during the 2-year follow-up period, a minority received palliative care (16.2%) or hospice (23.1%) services. Within 30 days of death, 84.5% of patients were hospitalized, and 61% died in the hospital. Among the patients who died, those who received intensive induction therapy (vs nonintensive therapy) spent 30% more of their life after diagnosis in the hospital (P < .0001) and were less likely to receive hospice services (odds ratio, 0.45; P = .05). CONCLUSIONS: The current findings highlight the intensity of health care utilization among older patients with AML, regardless of treatment modality. Despite the poor prognosis, palliative care and hospice services are rarely used. Future work should study novel health care delivery models to optimize care throughout the course of illness and at the end of life.
BACKGROUND: Health care utilization in older adults (age ≥60 years) with acute myeloid leukemia (AML) has not been well studied. METHODS: We conducted a retrospective analysis of 330 consecutive older patients who were diagnosed with AML between May 1, 2005 and December 23, 2011, at 2 hospitals in Boston to examine their health care utilization and end-of-life care. Using multivariable logistic and linear regression models adjusting for covariates, we also compared health care utilization between patients who received intensive induction chemotherapy (n = 197; cytarabine/ anthracycline combination) versus nonintensive chemotherapy (n = 133; single-agent therapy). RESULTS: The median number of hospitalizations for the entire cohort was 4.2 (range, 1-18 hospitalizations). Patients who died spent a mean of 28.3% of their life after diagnosis in the hospital and 13.8% of their life attending outpatient clinic appointments. Although the majority of patients (87.9%) died during the 2-year follow-up period, a minority received palliative care (16.2%) or hospice (23.1%) services. Within 30 days of death, 84.5% of patients were hospitalized, and 61% died in the hospital. Among the patients who died, those who received intensive induction therapy (vs nonintensive therapy) spent 30% more of their life after diagnosis in the hospital (P < .0001) and were less likely to receive hospice services (odds ratio, 0.45; P = .05). CONCLUSIONS: The current findings highlight the intensity of health care utilization among older patients with AML, regardless of treatment modality. Despite the poor prognosis, palliative care and hospice services are rarely used. Future work should study novel health care delivery models to optimize care throughout the course of illness and at the end of life.
Authors: B Löwenberg; R Zittoun; H Kerkhofs; U Jehn; J Abels; L Debusscher; C Cauchie; M Peetermans; G Solbu; S Suciu Journal: J Clin Oncol Date: 1989-09 Impact factor: 44.544
Authors: Hagop M Kantarjian; Xavier G Thomas; Anna Dmoszynska; Agnieszka Wierzbowska; Grzegorz Mazur; Jiri Mayer; Jyh-Pyng Gau; Wen-Chien Chou; Rena Buckstein; Jaroslav Cermak; Ching-Yuan Kuo; Albert Oriol; Farhad Ravandi; Stefan Faderl; Jacques Delaunay; Daniel Lysák; Mark Minden; Christopher Arthur Journal: J Clin Oncol Date: 2012-06-11 Impact factor: 44.544
Authors: Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf Journal: Blood Date: 2006-02-02 Impact factor: 22.113
Authors: C P Leith; K J Kopecky; I M Chen; L Eijdems; M L Slovak; T S McConnell; D R Head; J Weick; M R Grever; F R Appelbaum; C L Willman Journal: Blood Date: 1999-08-01 Impact factor: 22.113
Authors: J C Weeks; E F Cook; S J O'Day; L M Peterson; N Wenger; D Reding; F E Harrell; P Kussin; N V Dawson; A F Connors; J Lynn; R S Phillips Journal: JAMA Date: 1998-06-03 Impact factor: 56.272
Authors: Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield Journal: Blood Date: 2009-10-30 Impact factor: 22.113
Authors: Catherine Henckel; Anna Revette; Scott F Huntington; James A Tulsky; Gregory A Abel; Oreofe O Odejide Journal: J Pain Symptom Manage Date: 2020-01-09 Impact factor: 3.612
Authors: P Connor Johnson; Yian Xiao; Risa L Wong; Sara D'Arpino; Samantha M C Moran; Daniel E Lage; Brandon Temel; Margaret Ruddy; Lara N Traeger; Joseph A Greer; Ephraim P Hochberg; Jennifer S Temel; Areej El-Jawahri; Ryan D Nipp Journal: J Oncol Pract Date: 2019-04-04 Impact factor: 3.840
Authors: Samuel D Slavin; Alyssa Fenech; Amanda L Jankowski; Gregory A Abel; Andrew M Brunner; David P Steensma; Amir T Fathi; Daniel J DeAngelo; Martha Wadleigh; Gabriela S Hobbs; Philip C Amrein; Richard M Stone; Jennifer S Temel; Areej El-Jawahri Journal: Cancer Date: 2019-07-12 Impact factor: 6.860
Authors: Rong Wang; Amer M Zeidan; Stephanie Halene; Xiao Xu; Amy J Davidoff; Scott F Huntington; Nikolai A Podoltsev; Cary P Gross; Steven D Gore; Xiaomei Ma Journal: J Clin Oncol Date: 2017-08-07 Impact factor: 44.544
Authors: Heidi D Klepin; Janet A Tooze; Timothy S Pardee; Leslie R Ellis; Dmitriy Berenzon; Shannon L Mihalko; Suzanne C Danhauer; Arati V Rao; Tanya M Wildes; Jeff D Williamson; Bayard L Powell; Stephen B Kritchevsky Journal: J Am Geriatr Soc Date: 2016-09-14 Impact factor: 5.562